Dr Burke Pinpoints Top Trends from ASH 2024

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Chief Insights in Oncology:
Summary of ASH 2024 Pinpoints Top Trends Across Lymphoid Malignancies

John M. Burke, MD, discusses key findings from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and follicular lymphoma (FL), and providing insights into how these recent data may influence treatment strategies, particularly for community oncologists. Among the highlights, Burke explores the favorable results of the AMPLIFY trial (NCT03836261), which evaluated the combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for CLL, potentially paving the way for an FDA approval.

He also reflects on the updated findings from the TRIANGLE trial (NCT02858258), which further emphasize the benefit of adding ibrutinib (Imbruvica) to frontline therapy in MCL and suggests that autologous stem cell transplant (ASCT) may no longer be necessary for many patients.

Burke is associate chair of the US Oncology Hematology Research Program, a hematologist and medical oncologist at Rocky Mountain Cancer Centers in Aurora, Colorado, and one of the Editors-in-chief of Targeted Therapies in Oncology, a trusted resource for the latest updates in the field of oncology.

#Oncology #CommunityOncology #ASH #LymphoidMalignancies

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Category
Oncology
Be the first to comment

Up Next